Matt Barnes, Heptares Therapeutics president and head of UK R&D

So­sei Hep­tares part­ners with a UK-based can­cer re­search or­ga­ni­za­tion to bring its drug to tri­al

Can­cer re­search has been a fo­cus for So­sei Hep­tares for sev­er­al years, and their lat­est deal hopes to progress one of their new­er ther­a­pies.

On Fri­day, the Japan­ese com­pa­ny inked a deal with Can­cer Re­search UK to bring one of its can­cer drug can­di­dates in­to the clin­ic. Ac­cord­ing to So­sei, the agree­ment will have Can­cer Re­search UK run a Phase I/IIa tri­al of So­sei’s can­cer can­di­date HTL00397322, an EP4 an­tag­o­nist. The can­di­date will be eval­u­at­ed as both a com­bi­na­tion ther­a­py and a monother­a­py. While no ex­act fi­nan­cial de­tails were giv­en, So­sei will still hold the pro­gram’s li­cense af­ter the study reads out.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.